Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.

Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gómez Villanueva A, Pérez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M.

Ann Oncol. 2019 May 1;30(5):774-780. doi: 10.1093/annonc/mdz086.

2.

Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.

Barlaam B, Cadogan E, Campbell A, Colclough N, Dishington A, Durant S, Goldberg K, Hassall LA, Hughes GD, MacFaul PA, McGuire TM, Pass M, Patel A, Pearson S, Petersen J, Pike KG, Robb G, Stratton N, Xin G, Zhai B.

ACS Med Chem Lett. 2018 Jul 13;9(8):809-814. doi: 10.1021/acsmedchemlett.8b00200. eCollection 2018 Aug 9.

PMID:
30128072
3.

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.

Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, Yang Z, Riches L, Trinidad AG, Fok JHL, Hunt T, Pike KG, Wilson J, Smith A, Colclough N, Reddy VP, Sykes A, Janefeldt A, Johnström P, Varnäs K, Takano A, Ling S, Orme J, Stott J, Roberts C, Barrett I, Jones G, Roudier M, Pierce A, Allen J, Kahn J, Sule A, Karlin J, Cronin A, Chapman M, Valerie K, Illingworth R, Pass M.

Sci Adv. 2018 Jun 20;4(6):eaat1719. doi: 10.1126/sciadv.aat1719. eCollection 2018 Jun.

4.

Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice.

Karlin J, Allen J, Ahmad SF, Hughes G, Sheridan V, Odedra R, Farrington P, Cadogan EB, Riches LC, Garcia-Trinidad A, Thomason AG, Patel B, Vincent J, Lau A, Pike KG, Hunt TA, Sule A, Valerie NCK, Biddlestone-Thorpe L, Kahn J, Beckta JM, Mukhopadhyay N, Barlaam B, Degorce SL, Kettle J, Colclough N, Wilson J, Smith A, Barrett IP, Zheng L, Zhang T, Wang Y, Chen K, Pass M, Durant ST, Valerie K.

Mol Cancer Ther. 2018 Aug;17(8):1637-1647. doi: 10.1158/1535-7163.MCT-17-0975. Epub 2018 May 16.

PMID:
29769307
5.

The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).

Pike KG, Barlaam B, Cadogan E, Campbell A, Chen Y, Colclough N, Davies NL, de-Almeida C, Degorce SL, Didelot M, Dishington A, Ducray R, Durant ST, Hassall LA, Holmes J, Hughes GD, MacFaul PA, Mulholland KR, McGuire TM, Ouvry G, Pass M, Robb G, Stratton N, Wang Z, Wilson J, Zhai B, Zhao K, Al-Huniti N.

J Med Chem. 2018 May 10;61(9):3823-3841. doi: 10.1021/acs.jmedchem.7b01896. Epub 2018 May 2.

PMID:
29683659
6.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM.

Clin Cancer Res. 2018 May 1;24(9):2050-2059. doi: 10.1158/1078-0432.CCR-17-2260. Epub 2017 Oct 24.

7.

AKT Inhibition in Solid Tumors With AKT1 Mutations.

Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS.

J Clin Oncol. 2017 Jul 10;35(20):2251-2259. doi: 10.1200/JCO.2017.73.0143. Epub 2017 May 10. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):360.

8.

Simulation-Based Training - Evaluation of the Course Concept "Laparoscopic Surgery Curriculum" by the Participants.

Köckerling F, Pass M, Brunner P, Hafermalz M, Grund S, Sauer J, Lange V, Schröder W.

Front Surg. 2016 Aug 9;3:47. doi: 10.3389/fsurg.2016.00047. eCollection 2016.

9.

Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).

Degorce SL, Boyd S, Curwen JO, Ducray R, Halsall CT, Jones CD, Lach F, Lenz EM, Pass M, Pass S, Trigwell C.

J Med Chem. 2016 May 26;59(10):4859-66. doi: 10.1021/acs.jmedchem.6b00203. Epub 2016 Apr 22.

PMID:
27078757
10.

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.

Guichard SM, Curwen J, Bihani T, D'Cruz CM, Yates JW, Grondine M, Howard Z, Davies BR, Bigley G, Klinowska T, Pike KG, Pass M, Chresta CM, Polanska UM, McEwen R, Delpuech O, Green S, Cosulich SC.

Mol Cancer Ther. 2015 Nov;14(11):2508-18. doi: 10.1158/1535-7163.MCT-15-0365. Epub 2015 Sep 10.

11.

Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2.

Pike KG, Morris J, Ruston L, Pass SL, Greenwood R, Williams EJ, Demeritt J, Culshaw JD, Gill K, Pass M, Finlay MR, Good CJ, Roberts CA, Currie GS, Blades K, Eden JM, Pearson SE.

J Med Chem. 2015 Mar 12;58(5):2326-49. doi: 10.1021/jm501778s. Epub 2015 Feb 18.

PMID:
25643210
12.

Assessing needs and resources for the home visiting system in Alabama: a mixed methods approach.

Wingate MS, Fifolt M, Preskitt J, Mulvihill B, Pass MA, Wallace L, Sims D, McKim S.

Matern Child Health J. 2014 Jul;18(5):1075-84. doi: 10.1007/s10995-013-1335-5.

PMID:
23922159
13.

Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.

Addie M, Ballard P, Buttar D, Crafter C, Currie G, Davies BR, Debreczeni J, Dry H, Dudley P, Greenwood R, Johnson PD, Kettle JG, Lane C, Lamont G, Leach A, Luke RW, Morris J, Ogilvie D, Page K, Pass M, Pearson S, Ruston L.

J Med Chem. 2013 Mar 14;56(5):2059-73. doi: 10.1021/jm301762v. Epub 2013 Feb 26.

PMID:
23394218
14.

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.

Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, Martin NM, Ruston L, Pass SL, Pass M.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1212-6. doi: 10.1016/j.bmcl.2013.01.019. Epub 2013 Jan 18.

PMID:
23375793
15.

Prevalence and socioeconomic determinants of dental sealant use among schoolchildren in Saudi Arabia.

Al Agili DE, Niazy HA, Pass MA.

East Mediterr Health J. 2012 Dec;18(12):1209-16.

16.

Reaching and engaging non-gay identified, non-disclosing Black men who have sex with both men and women.

Benoit E, Pass M, Randolph D, Murray D, Downing MJ Jr.

Cult Health Sex. 2012 Oct;14(9):975-90. doi: 10.1080/13691058.2012.709640. Epub 2012 Aug 31. Erratum in: Cult Health Sex. 2012;14(10):1235.

17.

Physician behaviors surrounding the implementation of decision and communication AIDS in a breast cancer clinic: a qualitative analysis of staff intern perceptions.

Pass M, Volz S, Teng A, Esserman L, Belkora J.

J Cancer Educ. 2012 Dec;27(4):764-9. doi: 10.1007/s13187-012-0402-8.

PMID:
22923382
18.

Assessing the burden of Acinetobacter baumannii in Maryland: a statewide cross-sectional period prevalence survey.

Thom KA, Maragakis LL, Richards K, Johnson JK, Roup B, Lawson P, Harris AD, Fuss EP, Pass MA, Blythe D, Perencevich EN, Wilson L; Maryland MDRO Prevention Collaborative.

Infect Control Hosp Epidemiol. 2012 Sep;33(9):883-8. doi: 10.1086/667376. Epub 2012 Jul 23.

19.

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 1.

Delouvrié B, Al-Kadhimi K, Arnould JC, Barry ST, Cross DA, Didelot M, Gavine PR, Germain H, Harris CS, Hughes AM, Jude DA, Kendrew J, Lambert-van der Brempt C, Lohmann JJ, Ménard M, Mortlock AA, Pass M, Rooney C, Vautier M, Vincent JL, Warin N.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4111-6. doi: 10.1016/j.bmcl.2012.04.063. Epub 2012 Apr 21.

PMID:
22575869
20.

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2.

Delouvrié B, Al-Kadhimi K, Arnould JC, Barry ST, Cross DA, Didelot M, Gavine PR, Germain H, Harris CS, Hughes AM, Jude DA, Kendrew J, Lambert-van der Brempt C, Lohmann JJ, Ménard M, Mortlock AA, Pass M, Rooney C, Vautier M, Vincent JL, Warin N.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4117-21. doi: 10.1016/j.bmcl.2012.04.061. Epub 2012 Apr 21.

PMID:
22572578
21.

Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.

Oza V, Ashwell S, Almeida L, Brassil P, Breed J, Deng C, Gero T, Grondine M, Horn C, Ioannidis S, Liu D, Lyne P, Newcombe N, Pass M, Read J, Ready S, Rowsell S, Su M, Toader D, Vasbinder M, Yu D, Yu Y, Xue Y, Zabludoff S, Janetka J.

J Med Chem. 2012 Jun 14;55(11):5130-42. doi: 10.1021/jm300025r. Epub 2012 Jun 4.

PMID:
22551018
22.

Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors.

Oza V, Ashwell S, Brassil P, Breed J, Ezhuthachan J, Deng C, Grondine M, Horn C, Liu D, Lyne P, Newcombe N, Pass M, Read J, Su M, Toader D, Yu D, Yu Y, Zabludoff S.

Bioorg Med Chem Lett. 2012 Mar 15;22(6):2330-7. doi: 10.1016/j.bmcl.2012.01.043. Epub 2012 Feb 1.

PMID:
22342147
23.

Patient and observer ratings of physician shared decision making behaviors in breast cancer consultations.

Pass M, Belkora J, Moore D, Volz S, Sepucha K.

Patient Educ Couns. 2012 Jul;88(1):93-9. doi: 10.1016/j.pec.2012.01.008. Epub 2012 Feb 10.

PMID:
22322069
24.

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.

Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, Li J, Gao B, Ji Q, Maynard J, Ricketts SA, Cross D, Cosulich S, Chresta CC, Page K, Yates J, Lane C, Watson R, Luke R, Ogilvie D, Pass M.

Mol Cancer Ther. 2012 Apr;11(4):873-87. doi: 10.1158/1535-7163.MCT-11-0824-T. Epub 2012 Jan 31.

25.

Diverse heterocyclic scaffolds as allosteric inhibitors of AKT.

Kettle JG, Brown S, Crafter C, Davies BR, Dudley P, Fairley G, Faulder P, Fillery S, Greenwood H, Hawkins J, James M, Johnson K, Lane CD, Pass M, Pink JH, Plant H, Cosulich SC.

J Med Chem. 2012 Feb 9;55(3):1261-73. doi: 10.1021/jm201394e. Epub 2012 Jan 27.

PMID:
22248236
26.

Induction of heart valve lesions by small-molecule ALK5 inhibitors.

Anderton MJ, Mellor HR, Bell A, Sadler C, Pass M, Powell S, Steele SJ, Roberts RR, Heier A.

Toxicol Pathol. 2011 Oct;39(6):916-24. doi: 10.1177/0192623311416259. Epub 2011 Aug 22.

PMID:
21859884
27.

Human leukocyte antigen-G in the male reproductive system and in seminal plasma.

Larsen MH, Bzorek M, Pass MB, Larsen LG, Nielsen MW, Svendsen SG, Lindhard A, Hviid TV.

Mol Hum Reprod. 2011 Dec;17(12):727-38. doi: 10.1093/molehr/gar052. Epub 2011 Aug 3.

PMID:
21813635
28.

Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: optimization of the aniline.

Ducray R, Jones CD, Jung FH, Simpson I, Curwen J, Pass M.

Bioorg Med Chem Lett. 2011 Aug 15;21(16):4702-4. doi: 10.1016/j.bmcl.2011.06.090. Epub 2011 Jun 25.

PMID:
21764307
29.

Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration.

Oza V, Ashwell S, Brassil P, Breed J, Deng C, Ezhuthachan J, Haye H, Horn C, Janetka J, Lyne P, Newcombe N, Otterbien L, Pass M, Read J, Roswell S, Su M, Toader D, Yu D, Yu Y, Valentine A, Webborn P, White A, Zabludoff S, Zheng X.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5133-8. doi: 10.1016/j.bmcl.2010.07.015. Epub 2010 Jul 29.

PMID:
20673630
30.

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, James D, Howard Z, Dudley P, Hughes G, Smith L, Maguire S, Hummersone M, Malagu K, Menear K, Jenkins R, Jacobsen M, Smith GC, Guichard S, Pass M.

Cancer Res. 2010 Jan 1;70(1):288-98. doi: 10.1158/0008-5472.CAN-09-1751. Epub 2009 Dec 22.

31.

The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.

Malagu K, Duggan H, Menear K, Hummersone M, Gomez S, Bailey C, Edwards P, Drzewiecki J, Leroux F, Quesada MJ, Hermann G, Maine S, Molyneaux CA, Le Gall A, Pullen J, Hickson I, Smith L, Maguire S, Martin N, Smith G, Pass M.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5950-3. doi: 10.1016/j.bmcl.2009.08.038. Epub 2009 Aug 13.

PMID:
19762236
32.

Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.

Janetka JW, Almeida L, Ashwell S, Brassil PJ, Daly K, Deng C, Gero T, Glynn RE, Horn CL, Ioannidis S, Lyne P, Newcombe NJ, Oza VB, Pass M, Springer SK, Su M, Toader D, Vasbinder MM, Yu D, Yu Y, Zabludoff SD.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):4242-8. doi: 10.1016/j.bmcl.2008.05.016. Epub 2008 May 6.

PMID:
18547806
33.

Medicaid participation by private dentists in Alabama.

Al Agili DE, Pass MA, Bronstein JM, Lockwood SA.

Pediatr Dent. 2007 Jul-Aug;29(4):293-302.

PMID:
17867394
34.

Impact of advanced maternal age on neonatal survival of twin small-for-gestational-age subtypes.

Kristensen S, Salihu HM, Keith LG, Kirby RS, Pass MA, Fowler KB.

J Obstet Gynaecol Res. 2007 Jun;33(3):259-65.

PMID:
17578352
35.

Derangement of transcription factor profiles during in vitro differentiation of HL60 and NB4 cells.

Pass MB, Borregaard N, Cowland JB.

Leuk Res. 2007 Jun;31(6):827-37. Epub 2006 Aug 30.

PMID:
16942795
36.

SGA subtypes and mortality risk among singleton births.

Kristensen S, Salihu HM, Keith LG, Kirby RS, Fowler KB, Pass MA.

Early Hum Dev. 2007 Feb;83(2):99-105. Epub 2006 Jul 12.

PMID:
16842940
37.
38.

Infection control program disparities between acute and long-term care facilities in Maryland.

Roup BJ, Roche JC, Pass M.

Am J Infect Control. 2006 Apr;34(3):122-7.

PMID:
16630974
39.

Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.

Ballard P, Bradbury RH, Harris CS, Hennequin LF, Hickinson M, Johnson PD, Kettle JG, Klinowska T, Leach AG, Morgentin R, Pass M, Ogilvie DJ, Olivier A, Warin N, Williams EJ.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1633-7. Epub 2005 Dec 27.

PMID:
16380259
40.

Assuring public health professionals are prepared for the future: the UAB public health integrated core curriculum.

Petersen DJ, Hovinga ME, Pass MA, Kohler C, Oestenstad RK, Katholi C.

Public Health Rep. 2005 Sep-Oct;120(5):496-503. Review.

41.

Nosocomial malaria and saline flush.

Jain SK, Persaud D, Perl TM, Pass MA, Murphy KM, Pisciotta JM, Scholl PF, Casella JF, Sullivan DJ.

Emerg Infect Dis. 2005 Jul;11(7):1097-9.

42.

The association of child condition severity with family functioning and relationship with health care providers among children and youth with special health care needs in Alabama.

Mulvihill BA, Wingate MS, Altarac M, Mulvihill FX, Redden DT, Telfair J, Pass MA, Ellis DE.

Matern Child Health J. 2005 Jun;9(2 Suppl):S87-97.

PMID:
15973483
43.

An evaluation of a Medicaid managed maternity program: the impact of comprehensive care coordination on utilization and pregnancy outcomes.

Nason CS, Alexander GR, Pass MA, Bolland JM.

J Health Hum Serv Adm. 2003 Fall;26(2):239-67.

PMID:
15330491
44.

Access to dental care in Alabama for children with special needs: parents' perspectives.

Al Agili DE, Roseman J, Pass MA, Thornton JB, Chavers LS.

J Am Dent Assoc. 2004 Apr;135(4):490-5.

PMID:
15127874
45.

Correlating epidemiologic trends with the genotypes causing meningococcal disease, Maryland.

McEllistrem MC, Kolano JA, Pass MA, Caugant DA, Mendelsohn AB, Fonseca Pacheco AG, Shutt KA, Razeq J, Harrison LH; Maryland Emerging Infections Program.

Emerg Infect Dis. 2004 Mar;10(3):451-6.

46.

Hospitalizations and deaths due to Salmonella infections, FoodNet, 1996-1999.

Kennedy M, Villar R, Vugia DJ, Rabatsky-Ehr T, Farley MM, Pass M, Smith K, Smith P, Cieslak PR, Imhoff B, Griffin PM; Emerging Infections Program FoodNet Working Group.

Clin Infect Dis. 2004 Apr 15;38 Suppl 3:S142-8.

PMID:
15095183
47.

An evaluation of a Medicaid managed maternity program: the impact of comprehensive care coordination on utilization and pregnancy outcome.

Nason CS, Alexander GR, Pass MA, Bolland JM.

J Health Hum Serv Adm. 2002 Spring;24(4):493-521.

PMID:
15002703
48.

Aggregated antibiograms and monitoring of drug-resistant Streptococcus pneumoniae.

Van Beneden CA, Lexau C, Baughman W, Barnes B, Bennett N, Cassidy PM, Pass M, Gelling L, Barrett NL, Zell ER, Whitney CG.

Emerg Infect Dis. 2003 Sep;9(9):1089-95.

49.

Macrosomic births in the united states: determinants, outcomes, and proposed grades of risk.

Boulet SL, Alexander GR, Salihu HM, Pass M.

Am J Obstet Gynecol. 2003 May;188(5):1372-8.

PMID:
12748514
50.

Maternal and child health graduate and continuing education needs: a national assessment.

Alexander GR, Chadwick C, Slay M, Petersen DJ, Pass M.

Matern Child Health J. 2002 Sep;6(3):141-9.

PMID:
12236661

Supplemental Content

Support Center